ClinicalTrials.Veeva

Menu

Early Redox Biomarker Changes After Stellate Ganglion Block in Traumatic Brain Injury

U

University Medical Centre Ljubljana

Status

Completed

Conditions

Brain Injuries, Traumatic

Treatments

Other: Ultrasound-guided stellate ganglion block (parent study)

Study type

Observational

Funder types

Other

Identifiers

NCT07844811
0120-537/2019/15 (Other Identifier)
Oxidative Stress

Details and patient eligibility

About

Oxidative stress is a key mediator of secondary brain injury after traumatic brain injury (TBI). The stellate ganglion block (SGB) has been shown to modulate cerebral hemodynamics and neuroinflammation in brain-injured patients, but its effect on circulating redox biomarkers in human TBI has not been studied.

This is a post hoc secondary analysis of stored paired arterial and internal jugular venous blood samples from a prospective, single-center, before-and-after pilot study conducted at the University Medical Centre Ljubljana (parent trial: NCT04208477). Twenty adult patients with moderate-to-severe TBI (Glasgow Coma Scale score 12 or lower before intubation) who received a single ultrasound-guided SGB were included.

Paired blood samples collected at baseline and at 12 and 24 hours after SGB were assayed for derivatives of reactive oxygen metabolites (d-ROMs), plasma antioxidant capacity (PAT), the composite oxidative stress index (OSI = d-ROMs/PAT), the early lipid-peroxidation marker hexanoyl-lysine (HEL), and the oxidative DNA-damage marker 8-hydroxy-2'-deoxyguanosine (8-OHdG). No new intervention was administered, no additional patients were enrolled, and no additional biological samples were collected.

The primary outcome is the within-participant change in jugular venous OSI from baseline to 12 hours after SGB. Secondary outcomes include temporal changes in d-ROMs, HEL, and 8-OHdG in both arterial and jugular venous compartments, and the interaction between blood compartment and time. The statistical analysis plan for the oxidative-stress endpoints was documented before the biomarker assays were performed.

This pilot study provides variability estimates and preliminary data to inform the design of future controlled trials evaluating SGB as a potential modulator of post-traumatic oxidative stress.

Full description

Background and Rationale_____ Traumatic brain injury triggers a cascade of secondary injury mechanisms, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress. Reactive oxygen and nitrogen species overwhelm endogenous antioxidant defenses in the hours to days following injury, contributing to lipid peroxidation, protein oxidation, and DNA damage that exacerbate neuronal loss beyond the initial mechanical insult.

The stellate ganglion, located at the C7-T1 vertebral level, provides sympathetic innervation to the head, neck, and upper extremities. Blockade of this ganglion with local anesthetic has been used clinically for decades in the management of complex regional pain syndrome and other sympathetically mediated conditions. In cerebrovascular pathology, SGB has been associated with increased cerebral blood flow velocity, improved brain tissue oxygenation, and attenuation of neuroinflammatory markers. The parent study (NCT04208477) demonstrated favorable hemodynamic and oxygenation changes after SGB in TBI patients. Whether these hemodynamic effects are accompanied by measurable changes in the systemic and cerebral redox environment has not been investigated in humans.

The present post hoc analysis was designed to characterize the early temporal profile of circulating oxidative-stress biomarkers in paired arterial and internal jugular venous blood after SGB in moderate-to-severe TBI. The paired sampling strategy enables estimation of trans-cerebral gradients (jugular minus arterial concentration), providing indirect information about the balance of cerebral production and clearance of redox metabolites._____

Study Design_____

This is a secondary biomarker analysis embedded within a prospective, single-center, uncontrolled, before-and-after pilot study conducted at the surgical intensive care unit of the University Medical Centre Ljubljana, Slovenia (November 2021 to December 2023). The study was approved by the National Medical Ethics Committee of the Republic of Slovenia (approval KME RS 0120-537/2019/15) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the legally authorized representative of each patient, as participants were unable to consent due to their clinical condition.

Twenty adult patients (aged 18-80 years) with moderate or severe TBI, defined as a Glasgow Coma Scale (GCS) score of 12 or lower before tracheal intubation, who received a single ultrasound-guided left SGB as part of the parent study, were included. Paired arterial (radial artery catheter) and right internal jugular venous blood samples were collected at three time points: immediately before SGB (baseline), 12 hours post-SGB, and 24 hours post-SGB. Samples were centrifuged, aliquoted, and stored at -80 degrees Celsius until batch analysis._____

Biomarker Assays_____

The following redox biomarkers were measured in each paired sample:

d-ROMs: Measured using the Free Radical Analytical System (FRAS 5; H&D srl, Parma, Italy), reflecting circulating hydroperoxide-derived oxidant burden. Results expressed in Carratelli Units (U.CARR).

PAT: Measured on the same FRAS 5 platform, estimating total plasma antioxidant capacity to reduce ferric ions to ferrous ions. Results expressed in U.Cor.

OSI: Calculated as d-ROMs/PAT, a composite measure of the pro-oxidant/antioxidant balance. Higher values indicate greater oxidative stress.

HEL: An early-phase lipid peroxidation product, measured by enzyme-linked immunosorbent assay (ELISA). Reflects oxidative modification of polyunsaturated fatty acids at an early, reversible stage.

8-OHdG: A marker of oxidative DNA damage, measured by ELISA. Reflects hydroxyl radical attack on guanine residues in DNA._____

Statistical Analysis_____

The statistical analysis plan for the oxidative-stress endpoints was documented before laboratory assays were performed. The primary analysis tests the within-participant change from baseline in jugular venous OSI at 12 hours using a Wilcoxon signed-rank test, with the Hodges-Lehmann estimator and its 95% confidence interval as the effect measure. Secondary analyses apply repeated-measures approaches (Friedman test for time effects; Wilcoxon signed-rank tests for pairwise time-point and compartment comparisons) to d-ROMs, HEL, and 8-OHdG in both arterial and venous samples. Multiple comparisons are adjusted using the Holm-Bonferroni method. Exploratory Spearman correlations between redox biomarkers and inflammatory/brain-injury markers (IL-6, NSE, S100B, GFAP) are corrected using the Benjamini-Hochberg false discovery rate.

The sample size of 20 reflects the complete parent-study cohort. No separate power calculation was performed for this exploratory secondary analysis. Variability estimates from this pilot are reported to inform future sample-size planning for a controlled trial.

Enrollment

20 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with moderate or severe traumatic brain injury who participated in the original stellate ganglion block study (NCT04208477).
  • Glasgow Coma Scale score of 12 or lower before tracheal intubation.
  • Receipt of a single ultrasound-guided stellate ganglion block during the original study.
  • Availability of stored paired arterial and jugular venous blood samples collected at baseline and at the required post-block time points.
  • Availability of sufficient clinical and laboratory data to link the paired samples and determine their collection time relative to the stellate ganglion block.
  • Original informed consent provided by the participant's legally authorized representative permitted storage and subsequent scientific analysis of the collected samples.

Exclusion criteria

  • Absence of a baseline paired arterial and jugular venous blood sample.
  • Absence of suitable post-block samples required for the longitudinal analysis. Insufficient sample volume or sample quality for the planned redox biomarker analyses.
  • Samples failing prespecified laboratory quality-control criteria.
  • Incomplete or inconsistent sample identification or collection-time data preventing reliable pairing of arterial and jugular venous samples.
  • Withdrawal of consent or absence of authorization for secondary analysis of stored samples.

Trial design

20 participants in 1 patient group

Patients With Traumatic Brain Injury Previously Treated With Stellate Ganglion Block
Description:
A cohort of adult patients with moderate or severe traumatic brain injury who received an ultrasound-guided stellate ganglion block as part of a previously conducted clinical study. This post hoc study retrospectively analyzes stored paired arterial and jugular venous blood samples collected before and at 12 and 24 hours after the block. No intervention was assigned and no additional samples were collected specifically for the present analysis.
Treatment:
Other: Ultrasound-guided stellate ganglion block (parent study)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems